Fig. 11From: Ropivacaine as a novel AKT1 specific inhibitor regulates the stemness of breast cancerSchematic diagram of ropivacaine inhibiting the CSC-like traits of breast cancer cells. Ropivacaine targets AKT1 protein and inhibits its kinase activity, thereby blocking the NF-κB/GGT1 positive feedback loop and ultimately suppressing the CSC-like traits of breast cancer cellsBack to article page